Windsor Group LTD cut its position in Abbott Laboratories (NYSE:ABT) by 1.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 23,519 shares of the healthcare product maker’s stock after selling 360 shares during the quarter. Windsor Group LTD’s holdings in Abbott Laboratories were worth $2,575,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Atlas Private Wealth Advisors lifted its stake in Abbott Laboratories by 107.3% in the 4th quarter. Atlas Private Wealth Advisors now owns 228 shares of the healthcare product maker’s stock worth $25,000 after purchasing an additional 118 shares in the last quarter. Stuart Chaussee & Associates Inc. purchased a new stake in Abbott Laboratories in the 3rd quarter worth approximately $29,000. Black Swift Group LLC purchased a new stake in Abbott Laboratories in the 4th quarter worth approximately $35,000. PrairieView Partners LLC purchased a new stake in Abbott Laboratories in the 4th quarter worth approximately $41,000. Finally, Birchcreek Wealth Management LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at $44,000. Institutional investors and hedge funds own 72.58% of the company’s stock.

In other news, SVP Joseph J. Manning sold 18,750 shares of Abbott Laboratories stock in a transaction dated Monday, February 1st. The shares were sold at an average price of $122.79, for a total transaction of $2,302,312.50. Following the sale, the senior vice president now owns 81,561 shares of the company’s stock, valued at approximately $10,014,875.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Phebe N. Novakovic sold 4,790 shares of Abbott Laboratories stock in a transaction dated Friday, December 4th. The shares were sold at an average price of $107.28, for a total transaction of $513,871.20. Following the transaction, the director now directly owns 34,446 shares of the company’s stock, valued at $3,695,366.88. The disclosure for this sale can be found here. Insiders have sold a total of 24,045 shares of company stock worth $2,881,071 in the last ninety days. Insiders own 1.70% of the company’s stock.

Several analysts have recently weighed in on the stock. BTIG Research upgraded shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and set a $140.00 price objective on the stock in a research report on Thursday, January 28th. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $130.00 price objective on the stock in a research report on Tuesday, February 2nd. Wells Fargo & Company raised their price objective on shares of Abbott Laboratories from $128.00 to $137.00 in a research report on Thursday, January 28th. SVB Leerink raised their price objective on shares of Abbott Laboratories from $115.00 to $128.00 and gave the company a “market perform” rating in a research report on Thursday, January 28th. Finally, Raymond James lifted their target price on shares of Abbott Laboratories from $114.00 to $126.00 and gave the stock an “outperform” rating in a research report on Thursday, January 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and sixteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $122.26.

Abbott Laboratories stock traded down $1.78 during trading hours on Tuesday, reaching $120.77. The stock had a trading volume of 184,581 shares, compared to its average volume of 5,381,432. The stock has a market cap of $214.05 billion, a PE ratio of 64.84, a PEG ratio of 2.06 and a beta of 0.83. Abbott Laboratories has a 52 week low of $61.61 and a 52 week high of $128.54. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.70 and a quick ratio of 1.19. The company has a fifty day simple moving average of $118.10 and a 200-day simple moving average of $109.83.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Tuesday, January 26th. The healthcare product maker reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.10. The business had revenue of $10.70 billion for the quarter, compared to analyst estimates of $9.94 billion. Abbott Laboratories had a net margin of 10.50% and a return on equity of 18.19%. The company’s revenue was up 28.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.95 EPS. Research analysts predict that Abbott Laboratories will post 3.57 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, May 17th. Stockholders of record on Thursday, April 15th will be paid a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a dividend yield of 1.49%. The ex-dividend date is Wednesday, April 14th. Abbott Laboratories’s payout ratio is 55.56%.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. Its Established Pharmaceutical Products segment offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Read More: How is the discount rate different from the Federal Funds rate?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.